ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sunovion Pharmaceuticals and Otsuka Pharmaceutical have agreed to jointly develop four Sunovion compounds for psychiatric diseases. Sunovion will receive $270 million up front, plus milestone payments of up to $620 million. The compounds are ulotaront, a trace amine–associated receptor 1 agonist for the treatment of schizophrenia, in Phase 3 trials; a nonracemic ratio of amisulpride enantiomers for use in bipolar disorder, in Phase 3 trials; and depression and Alzheimer’s disease compounds in Phase 1 trials.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X